Context Therapeutics Inc.
9
2
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
44.4%
4 terminated/withdrawn out of 9 trials
20.0%
-66.5% vs industry average
0%
0 trials in Phase 3/4
200%
2 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Role: lead
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Role: lead
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Role: lead
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Role: collaborator
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Role: lead
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Role: lead
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Role: collaborator
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Role: collaborator
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Role: collaborator
All 9 trials loaded